Actifollic selling Pyrilutamide as a treatment for hair loss, with people debating its efficacy compared to Minoxidil and Finasteride in combination with RU58841.
A new product, a retinoic acid solution (0.3%), is available to enhance minoxidil products like Rogaine and Kirkland by converting them into a tretinoin-containing solution for improved hair loss treatment. One unit of the product is enough for a year's supply.
A user shared their 14-month progress using Pyrilutamide and Minoxidil for hair loss, noting improvement and no side effects with these treatments, unlike their negative experiences with Finasteride and RU58841. They emphasized the importance of consistent application for seeing results.
Nanoxidil is considered to have better absorption and fewer side effects than minoxidil, with added DHT blockers. The user is questioning if switching to the more expensive Spectral.DNC-N is worthwhile compared to cheaper options like Kirkland minoxidil.
The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
The user is considering changing their hair loss treatment from topical minoxidil and oral finasteride to oral minoxidil and oral dutasteride, with suggestions to add microneedling and possibly red light therapy. They are also exploring the addition of a caffeine and adenosine mix to their regimen.
A 33-year-old male is documenting his hair regrowth progress using minoxidil, red light therapy, copper peptides, and micro-needling, with noticeable improvement in hair thickness and coverage. He plans to add a topical finasteride/minoxidil spray and aims for a shadow on his scalp rather than a full head of hair.
The user, Albertgejmr, is happy with their progress in treating hair loss using 15mg oral minoxidil and 0.5mg Dutasteride. Some users express concern about the high dosage and potential side effects.
The user shared six months of progress using oral finasteride (1.2mg) and minoxidil (3mg) with positive results. They do not use topical minoxidil and have not experienced side effects like erectile dysfunction.
A user shared their one-year progress using finasteride, minoxidil, derma roller, ketosol shampoo, omega 3, biotin, daily exercise, and a positive outlook. They also discussed their exercise routine and addressed a question about finasteride side effects.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
The conversation discusses the potential role of prolactin in hair loss and mentions treatments like HMI115, mucuna pruriens, Zinc, and B6 P5P for lowering prolactin levels. It also touches on the use of natural compounds and the lack of studies due to funding issues.
The user has been using oral minoxidil 2.5 mg for 9 months and oral finasteride 1 mg for 4 months, along with microneedling, and has noticed more baby hairs and longer eyelashes but no extra overall thickness. They are considering increasing the minoxidil dose but are concerned about safety due to potential side effects.
A user shared their progress using 1.1mg oral finasteride and 3mg oral minoxidil since January 2024, noting significant improvement without side effects. They previously had an allergic reaction to topical treatments.
Discussing and researching different treatments for hair loss, including RU58841, Dutasteride, Spironolactone, Retin-A, Stemoxydine (Neogenic), Copper peptides, Superoxide Dismutase, NANO, and Eucapil.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.
The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The user has been using dutasteride, RU58841, and minoxidil for hair loss, experiencing some side effects and mixed results, with RU58841 notably reducing scalp itch. Despite extensive treatment, the user has maintained hair but struggles with hairline thickening.
A product with Minoxidil, finasteride, and RU58841 may help with hair thinning, but effectiveness varies, especially in aggressive cases. More potent treatments might be necessary for severe androgenetic alopecia (AGA).
The conversation discusses how to mix pyrilutamide for hair loss treatment, suggesting a mixture of 500mg pyrilutamide with 70% ethanol and 30% propylene glycol, and a potential application dose of 1mL. The user has not personally used pyrilutamide but has researched its preparation and application based on others' experiences.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
The user is using 1mg oral finasteride daily, topical minoxidil on the hairline, a dermaroller weekly, Alpecin Caffeine shampoo daily, and ketoconazole shampoo weekly. The hairline appears to be improving after two months.
OP used minoxidil for 15 months and pyrilutamide for 46 days, achieving desired results without side effects. Users discussed alternatives like dutasteride and finasteride, with concerns about side effects like erectile dysfunction.
PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.
The user shared progress pictures showing hair improvement from using oral finasteride and topical minoxidil between September 2023 and May 2026. Responses express amazement at the results.
The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.